Table 1.
Baseline characteristics of total cohort at enrollment and new-onset AF without HF at AF diagnosis
| Total Cohort at Enrollment (N=34,736) | New-Onset AF without HF at AF diagnosis (N=1495) | |
|---|---|---|
|
| ||
| Age, years | 55±7 | 69±8 |
|
| ||
| Race/ethnicity | ||
| White | 32,759 (94) | 1454 (97) |
| Black | 720 (2) | 12 (1) |
| Hispanic | 348 (1) | 4 (<1) |
| Other | 909 (3) | 25 (2) |
|
| ||
| BMI, kg/m2 | 26±5 | 28.1±6.1 |
|
| ||
| Diabetes mellitus, n (%) | 938 (3) | 172 (12) |
|
| ||
| Hypertension, n (%) | 9176 (26) | 1140 (76) |
| Systolic Blood Pressure, mmHg | ||
| <120 | 15324 (45) | 314 (21) |
| 120-139 | 14604 (43) | 826 (55) |
| 140-159 | 3970 (11) | 311 (21) |
| ≥160 | 406 (1) | 43(3) |
|
| ||
| Hyperlipidemia, n (%) | 10505 (30) | 954 (64) |
|
| ||
| History of coronary revascularization, n (%) | 0 (0) | 67 (5) |
|
| ||
| History of MI, n (%) | 0 (0) | 24 (2) |
|
| ||
| History of stroke, n (%) | 0 (0) | 36 (2) |
|
| ||
| Chronic Kidney Disease, n (%) | 7 (<1) | 12 (1) |
|
| ||
| Smoking status, n (%) | ||
| Never | 17920 (52) | 720 (48) |
| Past | 12484 (36) | 696 (47) |
| Current | 4306 (12) | 79 (5) |
|
| ||
| ≥ 2 drinks EtOH/day, n (%) | 1360 (4) | 91 (6) |
|
| ||
| Physical activity (≥ 7.5 METS/week) | 18923 (55) | 856 (57) |
|
| ||
| Anticoagulation use, n (%) | – | 663 (44) |
|
| ||
| CHADSVASc score* | ||
| 1 | 159 (11) | |
| 2 | 392 (26) | |
| 3 | – | 523 (35) |
| 4 | 349 (23) | |
| 5 | 55 (4) | |
| 6 | 16 (1) | |
| 7-9 | 1 (<1) | |
Continuous variables expressed mean±STDEV.
*
CHADSVASc score reflects thrombo-embolic risk: hypertension (1 point), age (65-74 years: 1 point; ≥ 75 years: 2 points), diabetes mellitus (1 point), history of stroke, TIA or thromboembolism (2 points), vascular disease (1 point), female sex (1 point). AF, atrial fibrillation; BMI, body mass index; EtOH, alcohol; METS, metabolic equivalents; ASA, aspirin.